ODS 656Alternative Names: ODS-656
Latest Information Update: 11 Feb 2016
At a glance
- Originator Oscotec
- Class Small molecules
- Mechanism of Action Osteoblast stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Osteoporosis
Most Recent Events
- 11 Feb 2016 Early research in Osteoporosis in South Korea (PO)